

# Disseminated Lupus Erythematosus and its Causes

Thomas Maroon\*

Department of Dermatology, University of Washington, Washington, USA

## DESCRIPTION

Disseminated Lupus Erythematosus (DLE), commonly known as Systemic Lupus Erythematosus (SLE), stands as a formidable challenge within the realm of autoimmune disorders. This intricate and multifaceted disease affects multiple organ systems, presenting a perplexing array of symptoms that often evade easy diagnosis and treatment. With its enigmatic nature, understanding DLE becomes crucial for patients, healthcare professionals, and researchers alike [1].

DLE is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues, causing inflammation and damage to various parts of the body. Although the precise cause of lupus remains elusive, a combination of genetic, environmental, and hormonal factors is believed to contribute to its development [2]. The character of DLE is its heterogeneity, as symptoms can range from mild to severe and vary greatly among individuals. Common manifestations encompass joint pain, skin rashes (often in a butterfly pattern across the cheeks and nose), fatigue, fever, hair loss, sensitivity to sunlight, and inflammation of organs such as the kidneys, heart, lungs, or brain. However, these symptoms often mimic those of other conditions, leading to diagnostic challenges [3].

Diagnosing DLE involves a comprehensive assessment of symptoms, medical history, physical examination, and laboratory tests. No single test can confirm lupus; hence, physicians rely on a combination of blood tests checking for specific antibodies (like anti-nuclear antibodies - ANA), imaging studies, and biopsies if organ involvement is suspected [4]. The impact of DLE extends beyond the physical realm, significantly affecting the emotional and mental well-being of patients. The unpredictable nature of the disease, chronic pain, and the need for ongoing medical management often lead to anxiety, depression, and feelings of isolation [5]. Coping mechanisms and a strong support system become invaluable for those grappling with the daily challenges of living with DLE.

Treatment strategies for DLE aim to manage symptoms, prevent flares, and minimize organ damage. Medications like Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), corticosteroids,

antimalarials, immunosuppressants, and biologics are often prescribed. Additionally, lifestyle modifications, including sun protection, regular exercise, and a balanced diet, play a crucial role in managing the disease [6]. Advancements in understanding DLE have led to promising avenues in treatment and management. Ongoing research focuses on identifying biomarkers for early diagnosis, unraveling genetic predispositions, and developing targeted therapies to mitigate the disease's progression. Biologics and immunotherapies hold significant promise, potentially offering more precise and effective treatments while minimizing adverse effects [7].

Raising awareness about DLE is pivotal in fostering understanding and empathy within society. Advocacy groups, patient communities, and educational campaigns play a crucial role in disseminating accurate information, supporting patients, and encouraging research efforts. Enhanced awareness not only aids in early detection but also reduces stigmatization and misconceptions surrounding the disease. Despite the strides made in understanding and managing DLE, numerous challenges persist [8]. The complexity of the disease demands a multidisciplinary approach involving rheumatologists, dermatologists, nephrologists, and other specialists. Additionally, access to specialized care, especially in underserved communities, remains a challenge, hindering timely diagnosis and optimal management.

As we march forward, the focus on patient-centric care, continued research endeavours, and improved accessibility to resources and treatments remains pivotal. Collaborative efforts among healthcare providers, researchers, patients, and advocacy groups are crucial in advancing our understanding and enhancing the quality of life for those battling the complexities of Disseminated Lupus Erythematosus [9,10].

## CONCLUSION

Disseminated Lupus Erythematosus stands as a poignant example of the intricate interplay between the immune system and the human body. By fostering awareness, advancing research, and providing comprehensive support, we endeavour to unravel its mysteries and pave the way toward more effective

**Correspondence to:** Thomas Maroon, Department of Dermatology, University of Washington, Washington, USA, E-mail: maroonthomas@gmail.com

**Received:** 01-Dec-2023, Manuscript No. LOA-23-28167; **Editor assigned:** 06-Dec-2023, Pre QC No. LOA-23-28167 (PQ); **Reviewed:** 20-Dec-2023, QC No. LOA-23-28167; **Revised:** 29-Dec-2023, Manuscript No. LOA-23-28167 (R); **Published:** 08-Jan-2024, DOI: 10.35248/2684-1630.23.8.274

**Citation:** Maroon T (2023) Disseminated Lupus Erythematosus and its Causes. *Lupus: Open Access*. 8:274.

**Copyright:** © 2023 Maroon T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

treatments, ultimately improving the lives of individuals affected by this challenging autoimmune disease.

## REFERENCES

1. Konar NR, Banerjee D. Disseminated lupus erythematosus. *Ind Med Gaz.* 1950;85(5):188-192.
2. Donaldson IM, Espiner EA. Disseminated lupus erythematosus presenting as chorea gravidarum. *Arch Neurol.* 1971;25(3):240-244.
3. Larrauri FR, Nakashimada MAY. Systemic lupus erythematosus: Is it one disease? *Reumatol Clin.* 2016;12(5):274-281.
4. Durcan L, ODwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. *Lancet.* 2019;393(10188):2332-2343.
5. Acevedo JSP, Varela DC, Hidron A. Concomitant onset of systemic lupus erythematosus and disseminated histoplasmosis: a case-based review. *Rheumatol Int.* 2021;41(9):1673-1680.
6. Gergianaki I, Bortoluzzi A, Bertias G. Update on the epidemiology, risk factors and disease outcomes of systemic lupus erythematosus. *Best Pract Res Clin Rheumatol.* 2018;32(2):188-205.
7. Ginzler EM, Dooley MA. Systemic lupus erythematosus. *Rheum Dis Clin North Am.* 2014;40(3):13-15.
8. Putterman C, Caricchio R, Davidson A, Perlman H. Systemic lupus erythematosus. *Clin Dev Immunol.* 2012;2012:437282.
9. Bourn R, James JA. Preclinical lupus. *Curr Opin Rheumatol.* 2015;27(5):433-439.
10. Julkunen H. Systemic lupus erythematosus. *Duodecim.* 2012;128(1):51-61.